Results 151 to 160 of about 365,877 (337)

Progress of Microsatellite (GT/CA)n Repeat Polymorphisms in Non-small Cell Lung Cancer

Zhongliu Fangzhi Yanjiu
Non-small cell lung cancer (NSCLC) is the most important histological type of lung cancer. This disease affects a large number of patients, and the prognosis of advanced patients is poor.
YANG Wenjun, FU Yuting, YUAN Yeqin, LIU Da, JIANG Binyuan   +4 more
doaj   +1 more source

Correction: Protein 4.1N acts as a potential tumor suppressor linking PP1 to JNK-c-Jun pathway regulation in NSCLC

, 2019
Zi Wang, Bianyin Ma, Hui Li, Xiaojuan Xiao, Weihua Zhou, Feng Liu, Bin Zhang, Min Zhu, Qin Yang, Yayue Zeng, Yang Sun, Shuming Sun, Yanpeng Wang, Yibin Zhang, Haibo Weng, Lixiang Chen, Mao Ye, Xiuli An, Jing Liu   +18 more
openalex   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Chromosomal Instability Identifies High‐Risk Patients With Early‐Stage Non‐Small Cell Lung Cancer

Cancer Nexus, EarlyView.
Chromosomal instability, as measured by fraction genome altered (FGA) from routine targeted next‐generation sequencing, identifies a high‐risk subgroup among patients with stage I–III non‐small cell lung cancer and provides prognostic information that is not captured by traditional clinical factors or tumor mutation burden. ABSTRACT Background Patients
Mobina Shrestha, Salina Dahal, Amir Babu, Yogesh Joshi   +3 more
wiley   +1 more source

A Comparison of Regional Decisions for Doses and Administrations of New Drugs: Concordance, Discordance, and Dependencies

Clinical Pharmacology &Therapeutics, EarlyView.
Regional differences in approved drug dosages and administration are shaped by complex factors, including clinical data, prior regulatory decisions, and region‐specific considerations. This study investigated how such factors are associated with variations in approved doses across the United States Food and Drug Administration (FDA), European Medicines
Sachiko Mita, Shunsuke Ono
wiley   +1 more source

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

Clinical Pharmacology &Therapeutics, EarlyView.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri, Islam R. Younis, Shadia I. Jalal, Theodore F. Logan, Rohan Maniar, Steven M. Bray, Sara K. Quinney, Zeruesenay Desta, Todd C. Skaar, James E. Tisdale, Tyler Shugg   +10 more
wiley   +1 more source

Erratum to: Potential unreliability of ALK variant allele frequency in the efficacy prediction of targeted therapy in NSCLC [PDF]

Wei Rao, Yutao Liu, Yan Li, Lei Guo, Tian Qiu, Lin Dong, Jianming Ying, Weihua Li   +7 more
openalex   +1 more source

Advanced extracellular vesicle immunotherapy

FlexMat, EarlyView.
A diagrammatic depiction of the therapeutic applicability of extracellular vesicles (EVs) in immunotherapy. This review explores the dual roles of tumor‐derived and immune cell‐derived EVs in cancer immunotherapy, discusses recent progress in EV engineering that improve their clinical utility, and evaluates their potential to augment existing ...
Jingjing Zhang, Yunfei Mu, Xianyue Ji, Xiaoting Jiang, Ruiheng Wang, Xianguang Ding, Lianhui Wang   +6 more
wiley   +1 more source

OA 12.01 The Preclinical and Clinical Activity of Poziotinib, a Potent, Selective Inhibitor of EGFR Exon 20 Mutant NSCLC [PDF]

, 2017
Yasir Y. Elamin, Jacqulyne Robichaux, Vincent K. Lam, Anne S. Tsao, Chien‐Hsing Lu, George Blumenschein, Jonathan M. Kurie, Julie R. Brahmer, S. Li, Ting Chen, Adriana Estrada‐Bernal, Anna Truini, Monique B. Nilsson, Anh T. Le, Zhi Tan, Shaozeng Zhang, Robert C. Doebele, Katerina Politi, Zane Yang, S. Liu, Kah Keng Wong, John V. Heymach   +21 more
openalex   +1 more source

Brain Metastases From Differentiated Thyroid Cancer in the Era of Targeted Therapies: A Multi‐Center Retrospective Cohort

Head &Neck, EarlyView.
ABSTRACT Background Brain metastases (BM) of differentiated thyroid carcinoma (DTC) are associated with unfavorable prognosis. This study evaluated BM management strategies and patients' outcomes. Methods A retrospective review of patients diagnosed with DTC and BM at Tel Aviv Sourasky and Rabin Medical Centers between 1985 and 2024. Clinical features,
Liyona Kampel, Shaun Edalati, Eyal Yosefof, Anton Warshavsky, Gilad Horowitz, Nidal Muhanna, Hagit Shoffel‐Havakuk, Eyal Robenshtok, Aron Popovtzer, Inbar Finkel   +9 more
wiley   +1 more source